Opinion
Video
Arvin K. George, MD, on the growing interest in focal therapy for prostate cancer
Author(s):
Key Takeaways
- Focal therapy for prostate cancer has shifted from skepticism to optimism over the past decade.
- Community-based practitioners and academic programs are increasingly adopting focal therapy.
“I would say, about 10 years ago, there was a real skepticism, a healthy skepticism, I would say, in the beginning. Now that has slowly changed into optimism,” says Arvin K. George, MD.
In this video, Arvin K. George, MD, describes how the adoption of focal therapy has evolved over the past few years. George is delivering a talk at the 2024 LUGPA Annual Meeting in Chicago, Illinois titled, “Focal Therapy: Killing Cancer Not the Prostate.”
George is an associate professor of clinical urology and director of the prostate cancer programs at Johns Hopkins Medicine in Baltimore, Maryland.
Video Transcript:
I think it's been really changing leaps and bounds every year. I would say, about 10 years ago, there was a real skepticism, a healthy skepticism, I would say, in the beginning. Now that has slowly changed into optimism. We're starting to see a number of community-based practitioners start to offer focal treatments within their practice. We're starting to see academic programs where, historically, they have been reluctant to initiate that process. Also, when we see what it looks like in the academic community, both from a societal standpoint—within professional organizations, I mean—and also within the literature, we're really starting to see publications in the area flourish, and sessions discussing it and talking about its potential really grow. The field has really grown in the in the last few years.
This transcript was AI generated and edited by human editors for clarity.
